Pay in 4 interest-free payments of $7.07 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
I walked in with anxiety and walked out with peace
This study population was then divided into two cohorts: (1) Semaglutide cohort 45,445 patients prescribed semaglutide, and (2) non-GLP1-RA anti-obesity medication cohort 37,744 patients prescribed non-GLP-1RA anti-obesity medications but not semaglutide
Based on a willingness-to-pay threshold of EUR 30,000 per QALY gained, oral semaglutide 14 mg was considered cost-effective versus empagliflozin 25 mg and dulaglutide 1.5 mg for the treatment of type 2 diabetes in Portugal
Precautions This product is not subject to a licensing process
Semaglutide is a GLP-1 receptor agonist that mimics the GLP-1 hormone - slowing gastric emptying, reducing appetite, triggering glucose-dependent insulin release, and suppressing glucagon
